Clearmind Medicine Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Clearmind Medicine announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events

• 1-for-10 Reverse Stock Split Announced

  The company will effect a 1-for-10 reverse share split, consolidating every ten common shares into one, effective May 21, 2026.

• Nasdaq Compliance Objective

  The primary purpose of the reverse split is to regain compliance with the Nasdaq Minimum Bid Price Rule, as the stock is trading near its 52-week low.

• Share Count Adjustment

  The number of issued and outstanding common shares will decrease from 10,190,337 to approximately 1,019,033. Authorized share capital remains unchanged.

• Fractional Shares Rounded Up

  No fractional shares will be issued; all fractional shares will be rounded up to the nearest whole common share.

auto_awesomeAnalysis

Clearmind Medicine is implementing a 1-for-10 reverse stock split, effective May 21, 2026, primarily to regain compliance with the Nasdaq Minimum Bid Price Rule. This action is critical for the company's continued listing on Nasdaq, as its stock is currently trading near its 52-week low. While necessary for compliance, reverse splits are generally viewed negatively by the market as they often indicate a company's struggle with a declining share price and can lead to reduced liquidity.